business
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.42% over the past month, so management has to make the case for its newly launched oral VK2735 Phase 3 program on this call.
Latest updates
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.42% over the past month, so management has to make the case for its newly launched oral VK2735 Phase 3 program on this call.